Reply  by Vatta, Matteo et al.
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ause Left Ventricular
oncompaction With Subclinical Myopathy?
n their article, Vatta et al. (1) showed that dilative cardio-
yopathy (DCM) is associated with cypher (Z-band
lternatively-spliced PDZ-motif-protein) gene mutations in
xons 4, 6, and 10 in 6% of the cases. Additionally, mutant
ypher-gene-transfected myoblasts developed cytoskeletal dis-
rray (1). Their findings raise the following concerns: It is not
entioned which clinical and echocardiographic criteria for
CM were applied. Were patients with DCM due to coro-
ary heart disease also included, or did all patients have normal
oronary angiograms? It remains unclear according to which
riteria left ventricular hypertrabeculation/noncompaction
LVHT/NC) was diagnosed (2,3). It is not indicated whether
atients with DCM were consecutively or selectively included
nd how many centers recruited the patients during which
eriod. Did relatives of all 100 patients or only those of
ypher-gene mutation carriers undergo clinical cardiologic and
eurologic examination, creatine-kinase determination, and
enetic studies? How was cardiac affection defined? It is
nclear why patient II:1 (family 065) was classified as cardio-
ogically normal, although, according to their Table 3, no
chocardiographic examinations were performed. Further-
ore, the description of a “mildly dilated left ventricle” in
atient III:1 does not match Table 3, indicating that echocar-
iography was not carried out at all in this patient. Concerning
he authors’ speculations that mutations in the skeletal muscle
ypher-isoform may go along with fatigue and exercise intol-
rance, it would be interesting to know whether any of the
utation carriers complained about symptoms suggestive of a
euromuscular disorder. How do the authors explain that
ypher knock-out mice develop severe myopathy, whereas
umans with cypher-mutations were neurologically normal?
ormal clinical neurologic examination and normal creatine
inase, however, do not rule out myopathy. It is not clear
hether the skeletal muscle cypher-isoform was regularly
xpressed in the skeletal muscle. Did any of the patients
ndergo muscle biopsy? It appears as if the 200 control subjects
ad not undergone clinical cardiologic or neurologic investiga-
ions. Did any of these probands have DCM or LVHT/NC?
t remains unclear how mutations in exon 4 were exclusively
ssociated with LVHT/NC although the inclusion criterion
as DCM. Did the authors find mutation carriers without
linical affection? It is not mentioned how many of the patients
ith cypher mutations also had LVHT/NC. Concerning their
able 3, the title is misleading because not all patients had
ypher-mutations. It also is not explained from which mea-
urements the standard deviation was calculated. Were patients
epeatedly investigated or does it derive from a non-described
ontrol group? Figure 1B erroneously shows a 352M instead ofI352M mutation. The authors do not mention that eVHT/NC may be also associated with mutations in the
MPK, DMD, AMPD1, and mitochondrial gene(s) (4–6).
verall, the study lacks proper characterization of the pheno-
ype and control group. Criteria for cardiac affection are
mbiguous. Although the study nicely shows cypher-mutations
o be associated with LVHT/NC, the prevalence of this
ssociation remains uncertain. To further clarify the pathoge-
etic background of LVHT/NC, we suggest that patients with
VHT/NC should undergo thorough investigation of the
keletal muscle in the light of previous findings, according to
hich LVHT/NC is associated with myopathies in up to
our-fifths of these patients (3).
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EPLY
e would like to thank Drs. Finsterer and Stollberger for
heir comments. Our study (1) was performed on patients
ith left ventricular (LV) dysfunction associated with classic
ilated cardiomyopathy (DCM) or left ventricular non-
ompaction (LVNC). All patients had standard echocardio-
raphic evaluations and/or cardiac magnetic resonance im-
ging with selected cases having cardiac catheterization and
ngiography. Because the vast majority of patients evaluated
ither had classic autosomal-dominant inheritance and/or
ere of a young age, coronary angiography was not indi-
ated in many of these subjects. In addition, no patient had
vidence of regional wall abnormalities on echocardiogra-
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September 1, 2004:1139–45hy. The criteria used for definition of LVNC is that
escribed by Chin et al. (2), Ichida et al. (3), Pignatelli et al.
4), and Towbin and Bowles (5), which is the accepted
riteria by cardiologists. The patients screened were re-
ruited from five centers; all of the patients were evaluated
y cardiac and neurologic analyses. All nuclear family
embers were evaluated by cardiac exam and genetic
creening; selected subjects (but the majority) were also
creened neurologically. Regarding subject II:1 of family
65, she is the wife of an affected family member. Her
chocardiogram was read as normal, but the specific mea-
urements were not available. It should be noted that she is
ot a “blood relationship” of the affected family members
except her daughter, whose father was affected). Symptom-
tically (as noted), the affected patients commonly com-
lained of muscle fatigue and cramping as well as exercise
ntolerance. Because these patients were, in most cases,
ffectively treated for heart failure, these symptoms are
eyond expectations for clinically stable, compensated car-
iomyopathy and suggest a primary skeletal muscle func-
ional abnormality. Cypher knock-out mice do have “clini-
al myopathy” that is probably more severe than our patients
s a result of the heterozygous nature of our mutations (and
he total loss of function of the knock-out animals). This is
ommon when comparing mouse knock-out models with
utosomal-dominant human subjects. We have shown this
o be the case here as well as in several other publications in
hich we identified causative genes for DCM (-
arcoglycan, dystrophin, MLP, -actinin2) (5,6), and
VNC (-dystrophin, G4.5) (3).
The 200 control patients are standardized controls as
sed in all genetic studies; none had DCM, LVNC, or
ardiac disease (that is why they are called controls). Based
n their comments regarding the knock-out animals and
hese statements regarding the control analyses, it is clear
hat Drs. Finsterer and Stöllberger (7) do not understand
uman molecular genetics and do not understand the
enetic basis of cardiomyopathy. Their queries regarding
he clinical data also demonstrate that they are clearly not
ardiologists and have no experience or understanding of
hese clinical diseases. Furthermore, although we agree with
heir suggestion that studies of skeletal muscle in patients
ith LVNC should be considered, it should be noted that in
heir own publications, they are unable to study the skeletal
uscle of over 50% of cases with LVNC. How they can
uggest that 80% of cases have associated skeletal muscle
isease is unclear because they themselves have failed to
erform these analyses. Regarding the points raised about
ther causes of LVNC, we have now shown that LVNC is
genetically heterogeneous disorder with autosomal-
ominant inheritance resulting from mutations in
-dystrobrevin and Cypher/ZASP (1), as well as being
ssociated with X-linked inheritance due to mutations in
4.5 (3). No genetic data are available to demonstrate
itochondrial inheritance thus far. Clearly, the disorder isomplex, and further study is needed. Why ZASP mutations rause LVNC in some individuals and DCM in others is not
et known.
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evere Ostial Saphenous Vein
raft Disease Leading to Acute
oronary Syndromes After Proximal
orto-Saphenous Anastomoses With
he Symmetry Bypass Connector Device
read the article by Cavendish et al. (1) with interest. They
escribed their experience with 320 applications of the
ymmetry Aortic Connector (St. Jude Medical Inc., St.
aul, Minnesota) in 121 patients. There were 11 (3%)
escribed failures (proximal occlusion or ostial stenoses).
hey do not, however, describe the sizes used (gray, green,
lue, purple), the quality of the conduit, or the quality/size
f the distal target in any of the cases. Furthermore, they do
ot describe the anticoagulation protocol they followed after
sing this device.
My colleagues and I also have extensive experience with
his device. We recognized early in our experience that
ecause this product is composed of nitinol, it should be
egarded as an intra-coronary stent. To that end, we
outinely anticoagulate on postoperative day 1 with clopi-
